This is a working overview of TH9507, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-24. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
== Pharmacology == GnRH antagonists competitively and reversibly bind to GnRH receptors in the pituitary gland, blocking the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary. In men, the reduction in LH subsequently leads to rapid suppression of testosterone production in the testes; in women it leads to suppression of estradiol and progesterone production from the ovaries. GnRH antagonists are able to abolish gonadal sex hormone production and to suppress sex hormone levels into the castrate range, or by approximately 95%. Unlike the GnRH agonists, which cause an initial stimulation of the hypothalamic–pituitary–gonadal axis (HPG axis) that leads to a surge in testosterone or estrogen levels, GnRH antagonists have an immediate onset of action and rapidly reduce sex hormone levels without an initial surge.
=== Jason: The Pretty-Boy Bully === First aired 3 September 2009 Jason gets in the ring with MMA fighter Jon Murphy. Out of the $5,000 he could have won in the first round, Jason walked away with $2,000, and in the kick boxing round lost and the Victims got the $5,000. After giving Jason a wedgie, Mayhem refers to the bully beatdown as 'God's Work'. Victims- Step Brother, and friend from High school
In animal and Human biology, a tendon cell is a cell that makes up tendons, the bands of connective tissue that connects muscles to bones. Tendon cells, also known as tenocytes or tendon fibroblasts, are specialized cells that contribute to the structure, function, and repair of tendons in the body. Tendons are fibrous tissues that connect muscles to bones, and tendon cells play a vital role in maintaining tendon homeostasis and facilitating healing following injury.
Sources: en.wikipedia.org
=== Fortification === The World Health Organization does not have any recommendations for food fortification with vitamin E. The Food Fortification Initiative does not list any countries that have mandatory or voluntary programs for vitamin E. Infant formulas have alpha-tocopherol as an ingredient. In some countries, certain brands of ready-to-eat cereals, liquid nutrition products, and other foods have alpha-tocopherol as an added ingredient.
== Genetic engineering == The origins of biotechnology culminated with the birth of genetic engineering. There were two key events that have come to be seen as scientific breakthroughs beginning the era that would unite genetics with biotechnology. One was the 1953 discovery of the structure of DNA, by Watson and Crick, and the other was the 1973 discovery by Cohen and Boyer of a recombinant DNA technique by which a section of DNA was cut from the plasmid of an E. coli bacterium and transferred into the DNA of another. This approach could, in principle, enable bacteria to adopt the genes and produce proteins of other organisms, including humans. Popularly referred to as "genetic engineering," it came to be defined as the basis of new biotechnology. Genetic engineering proved to be a topic that thrust biotechnology into the public scene, and the interaction between scientists, politicians, and the public defined the work that was accomplished in this area. Technical developments during this time were revolutionary and at times frightening. In December 1967, the first heart transplant by Christiaan Barnard reminded the public that the physical identity of a person was becoming increasingly problematic. While poetic imagination had always seen the heart at the center of the soul, now there was the prospect of individuals being defined by other people's hearts. During the same month, Arthur Kornberg announced that he had managed to biochemically replicate a viral gene. "Life had been synthesized," said the head of the National Institutes of Health.
Other studies have found higher rates of link rot in academic literature but typically suggest a half-life of four years or greater. A 2013 study in BMC Bioinformatics analyzed nearly 15,000 links in abstracts from Thomson Reuters's Web of Science citation index and found that the median lifespan of web pages was 9.3 years, and just 62% were archived. A 2021 study of external links in New York Times articles published between 1996 and 2019 found a half-life of about 15 years (with significant variance among content topics) but noted that 13% of functional links no longer lead to the original content—a phenomenon called content drift. A 2013 study found that 49% of links in U.S. Supreme Court opinions are dead. A 2023 study looking at United States COVID-19 dashboards found that 23% of the state dashboards available in February 2021 were no longer available at the previous URLs in April 2023. Pew Research found that, in 2023, 38% of pages from 2013 went missing. Also, in 2023, 54% of English Wikipedia articles had a dead link in the 'references' section and 23% of news articles linked to a dead URL.
Sources: en.wikipedia.org
==== Gel electrophoresis under non-denaturing conditions ==== Non-denaturing gel electrophoresis allows proteins to maintain their native structure while being separated. This method is useful for studying protein-protein interactions and enzyme activities. Proteins migrate through the gel based on their size and charge, but their functional properties remain intact, making it ideal for analyzing native protein complexes.
== Distribution == Teleosts are found worldwide and in most aquatic environments, including warm and cold seas, flowing and still freshwater, and even, in the case of the desert pupfish, isolated and sometimes hot and saline bodies of water in deserts. Teleost diversity becomes low at extremely high latitudes; at Franz Josef Land, up to 82°N, ice cover and water temperatures below 0 °C (32 °F) for a large part of the year limit the number of species; 75 percent of the species found there are endemic to the Arctic.
== History == Diabulimia is not currently recognised in the DSM-5. Current diagnoses are based on the idea of insulin restriction being a feature of existing anorexia nervosa and bulimia nervosa. Diabulimia is gaining notability within scientific research. In 2019, NHS England began trialling specialist diabulimia clinics. Whilst access to eating disorder clinics is improving, access to specialist diabulimia services is not widely available.
== Blood levels == Blood levels are in the pmol/L or fmol/mL range. Both active and total ghrelin can be measured. Circulating ghrelin concentrations rise before eating and fall afterward, more strongly in response to protein and carbohydrate than to lipids. The plasma ghrelin-like immunoreactivity concentration measured with a particular radioimmunoassay in a typical human is 166.0 + 10.1 fmol/mL. Serum ghrelin concentrations tend to increase in age and vary throughout the day, with values peaking while one is asleep.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.